Related Experiment Video

Updated: May 9, 2026

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β

Jonathan Arauz1, Natanael Zarco, José Segovia

  • 1Departments of aPharmacology bPhysiology, Biophysics and Neuroscience cInfectomics and Molecular Pathogenesis, Cinvestav-IPN., Mexico, D.F. Mexico.

European Journal of Gastroenterology & Hepatology
|August 2, 2013
PubMed
Abstract

Insights

Caffeine effectively prevents liver cirrhosis in rats by reducing liver damage and inflammation. Its antioxidant properties and ability to block key fibrotic factors are key to its protective effects.

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Emerging evidence suggests caffeine benefits liver health.
  • Molecular mechanisms underlying caffeine's hepatoprotective effects require further elucidation.

Purpose of the Study:

  • To investigate caffeine's efficacy in preventing thioacetamide (TAA)-induced liver cirrhosis in a rat model.
  • To explore the underlying mechanisms of caffeine's protective action against liver fibrosis.

Main Methods:

  • Liver cirrhosis was induced in rats via chronic TAA administration.
  • Caffeine was co-administered for 8 weeks, with control groups included.
  • Liver enzymes, histopathology, hydroxyproline, redox balance, and fibrogenic markers were assessed.

Main Results:

  • Caffeine administration inhibited TAA-induced liver cirrhosis and prevented elevated liver enzymes.
  • Caffeine treatment significantly reduced liver histopathology and hydroxyproline levels.
  • Caffeine demonstrated antioxidant properties, restored redox equilibrium, and blocked key profibrogenic factors like TGF-β and CTGF.

Conclusions:

  • Caffeine prevents experimental liver cirrhosis through antioxidant mechanisms.
  • Caffeine's antifibrotic action is primarily mediated by blocking transforming growth factor-β (TGF-β) signaling.
  • These effects contribute to the attenuation of hepatic inflammation and fibrotic processes.

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...